According to a new study presented at the Society of Nuclear Medicine’s 2012 Annual Meeting, a customized patch treatment is capable of destroying basal cell carcinoma facial tumors without the need for major radiation treatment or surgery in 80 percent of the patients in the study.
Basal cell carcinoma is the most common type of skin cancer, a non-melanoma type of cancer that affects the surface layer of the skin.
The new phosphorus-32 (P-32) patch is a radiation spot treatment that can be applied to patient’s skin cancer during a few outpatient appointments. Researchers say it is ideal for people whose skin cancer is located in areas where it is difficult to operate on (such as the eyes, nose, or forehead) or would require challenging skin grafting after surgery. The investigators say it has many advantages over many of the current treatments for basal cell carcinoma in that it does not require a hospital admission, is simple to utilize, and is relatively inexpensive.
More studies will be required before the P-32 patch can be approved for general use, the scientists say, but they are optimistic given these initial results.
According to the World Health Organization, about 2 to 3 million non-melanoma skin cancers develop worldwide every year. Among Americans, one in five people will develop basal cell carcinoma in their lifetime.
Source: Society of Nuclear Medicine